Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

canertinib dihydrochloride

(can-ER-tih-nib dy-HY-droh-KLOR-ide)

A substance being studied in the treatment of some types of cancer. Canertinib dihydrochloride blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor. Also called CI-1033.

canertinib dihydrochloride

Search NCI's Dictionary of Cancer Terms